These results will provide a new understanding of the resistance mechanisms of anti-PD-1/PD-L1 therapy in NPC, and suggest that targeting TGF-β1 pathway might be a promising approach to enhance immune checkpoint blockade in NPC. The gene discussed is PDCD1; the disease is nasopharyngeal carcinoma.